Additionally, we show this pathway is not only inhibited by, but inverted by, NDD-associated mutations in Trio-GEF1, positioning Sema3A-pCRMP2-Trio signaling as a potential therapeutic target for Trio-related NDDs. The gene discussed is ARHGEF1; the disease is Neurodevelopmental delay.